Axsome rises as U.S. FDA accepts migraine treatment application

IPI Legacy Liquidation Co

14/09/2021 12:57

** Shares of drug developer  AXSM.O  rise 7.9% to $29.64
premarket, on track for a fourth straight session of gains
    ** Co says the U.S. FDA has accepted the marketing
application for its oral migraine treatment and has set a target
action date of April 30, 2022  urn:newsml:reuters.com:*:nGNX8YKg0x
    ** The news comes after the U.S. FDA delayed its decision on
AXSM's depression drug in August  urn:newsml:reuters.com:*:nL4N2PU2HJ
    ** The current migraine therapy market is crowded with oral
drugs such as Biohaven's  BHVN.N  Nurtec ODT, however, symptoms
such as nausea and vomiting experienced by patients during
attacks could impact their effectiveness
    ** Impel NeuroPharma Inc  IMPL.O  earlier in September
received U.S. approval for its nasal spray to treat migraine
 urn:newsml:reuters.com:*:nL4N2Q52SO
    ** AXSM stock down 66.3% this year, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))